A strategy of CTCA with selective FFRCTÂ in patients with stable angina did not differ significantly from standard clinical care pathways in cost or clinical outcomes, but did reduce the use of invasive coronary angiography.
🔵 Coronary CTangiography as an ‘onestop shop’ to detect the high-risk plaque and the vulnerable patient
🔵 A ‘Once-and-Done’ Approach to the Lifelong Reduction of Elevated Cholesterol
To introduce a precise single-nucleotide PCSK9 loss-of-function mutation, a CRISPR ABE was delivered in macaques using lipid nanoparticles (LNPs). Adenine base editors of PCSK9 was confirmed in primary human hepatocytes, primary monkey hepatocytes, and mice.
In vivo CRISPR ABE delivery led to a near-complete knockdown of PCSK9 in the liver after a single infusion of LNPs, with concomitant reductions in blood levels of PCSK9 and LDL-C of 90% and 60%, respectively. These changes were sustained for at least 8 months after a single-dose treatment. No relevant side effects were observed in the animals treated with a CRISPR editor-based strategy.
🔵 NHATS - Frailty and cardiovascular outcomes in the National Health and Aging Trends Study
In patients without CHD, frailty is a risk factor for the development of MACEs. Efforts to identify frailty in patients without CHD and interventions to limit or reverse frailty status are needed and, if successful, may limit subsequent adverse cardiovascular events.
🔴 **EBC MAIN The European bifurcation club Left Main Coronary Stent study**
Among patients with true bifurcation left main stem stenosis requiring intervention, fewer major adverse cardiac events occurred with a stepwise layered provisional approach than with planned dual stenting, although the difference was not statistically significant. The stepwise provisional strategy should remain the default for distal left main stem bifurcation intervention.